Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Common Antioxidant Might Slow Parkinson's

But too much urate can also cause trouble, so more study is needed, experts say

By Ed Edelson
HealthDay Reporter


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Acoustic Neurinoma
Adhesions
More...

Related Healthscout Videos
 border=
Shutting Down Tremor.
Weighted Belt for Autism?
Helping Jude Talk
Hungry Heart
More...

Related Animations
 border=
GERD
PPI Therapy
What is Cholesterol?
More...

Related Drug Information
 border=
Aciphex
Adderal XR
Concerta
Coumadin
More...

Related News Articles
 border=
Deadly Stomach Bug Making Inroads Outside Hospitals
Living With Less TV, More Sweat Boosts Weight Loss
Folate Levels in Pregnancy Tied to ADHD in Offspring
Sugar Shortens Life Span in Worms
More...

TUESDAY, Oct. 13 (HealthDay News) -- A new look at some old data adds convincing evidence that high body fluid levels of the antioxidant urate slow the progressive nerve damage of Parkinson's disease.

However, the researchers also warned of the potential danger of putting that information to immediate use.

Text Continues Below



"The study doesn't prove that urate is slowing down the disease, and we need clinical trials to see if progression is based on levels of urate," explained study senior author Dr. Michael A. Schwarzschild, associate professor of neurology at Harvard Medical School and director of the MassGeneral Institute for Neurodegenerative Diseases. He and his colleagues reported the finding online Oct. 12 in the Archives of Neurology.

A clinical trial assessing the impact of urate on Parkinson's is beginning, funded by the Michael J. Fox Foundation. It is recruiting 90 people with Parkinson's disease at 10 U.S. medical centers to study whether regular intake of inosine, a widely available dietary supplement that is a precursor of urate, slows Parkinson's-related deterioration of nerves. Results are expected to be available in about two years, but more definitive studies will take five years or longer, Schwarzschild said.

Meanwhile, what should people with Parkinson's disease do? "They should be very cautious," Schwarzschild said. "There may be a temptation, but one should be careful because there are clear safety concerns."

The major dangers of overdosing with urate are kidney stones and gout, but there are other possible risks, such as an increased incidence of cardiovascular disease, he said.

"There is a lot of vice associated with it, and because we don't know if the case is proven, it would be bad advice to take such measures," Schwarzschild said.

Another expert agreed. "I would not at this point recommend to any Parkinson's patients that they take inosine as a supplement," said Dr. Ira Shoulson, professor of neurology at the University of Rochester in New York and a member of the research team. "I would not for several reasons, mostly to do with safety but also about whether it is beneficial. These are things we have to sort out in future years."

Page:  1 | 2 | Next >>

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 10/13/2009

Related Links
 border=
From Healthscout's partner site on alzheimer's disease, OurAlzheimers.com
I need to know about Alzheimer's symptoms.
What are the stages of Alzheimer's Disease?
Learn about Alzheimer's medications.





SOURCES: Michael A. Schwarzschild, M.D., Ph.D, associate professor, neurology, Harvard Medical School, director, MassGeneral Institute for Neurodegenerative Diseases, Boston; Ira Shoulson, M.D., professor, neurology, University of Rochester, N.Y.; Melissa Nirenberg, M.D., Ph.D., assistant professor, neurology and neuroscience, Weil Cornell Medical College in New York City; online Oct. 12, 2009, and December 2009 print edition of Archives of Neurology


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy